Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T.

Int J Hematol. 2010 Nov;92(4):624-33. doi: 10.1007/s12185-010-0692-8. Epub 2010 Oct 5.

PMID:
20890793
[PubMed - indexed for MEDLINE]
2.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S.

Blood. 2007 Jan 1;109(1):315-22. Epub 2006 Aug 15.

PMID:
16912224
[PubMed - indexed for MEDLINE]
Free Article
3.

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC.

Cancer Res. 2006 Jan 1;66(1):473-81.

PMID:
16397263
[PubMed - indexed for MEDLINE]
Free Article
4.

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.

Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.

Leuk Res. 2006 May;30(5):575-82. Epub 2005 Oct 6.

PMID:
16213582
[PubMed - indexed for MEDLINE]
5.

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 Mar 7;12:19. doi: 10.1186/1476-4598-12-19.

PMID:
23497317
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.

Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L.

Leuk Res. 2011 Sep;35(9):1212-8. doi: 10.1016/j.leukres.2011.05.014. Epub 2011 May 31.

PMID:
21632108
[PubMed - indexed for MEDLINE]
7.

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H.

Leuk Res. 2006 Nov;30(11):1365-70. Epub 2006 Jun 23.

PMID:
16797704
[PubMed - indexed for MEDLINE]
8.

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

Corbin AS, Griswold IJ, La Rosée P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW.

Blood. 2004 Dec 1;104(12):3754-7. Epub 2004 Aug 10.

PMID:
15304388
[PubMed - indexed for MEDLINE]
Free Article
9.

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Exp Hematol. 2010 Sep;38(9):782-91. doi: 10.1016/j.exphem.2010.05.004. Epub 2010 May 26.

PMID:
20685234
[PubMed - indexed for MEDLINE]
10.

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.

Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J.

Mol Cancer Ther. 2010 Jan;9(1):211-23. doi: 10.1158/1535-7163.MCT-09-0468. Epub 2010 Jan 6.

PMID:
20053766
[PubMed - indexed for MEDLINE]
Free Article
11.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K.

Blood. 2005 Feb 15;105(4):1768-76. Epub 2004 Oct 28.

PMID:
15514006
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.

Pan J, Quintás-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S.

Cancer Sci. 2007 Aug;98(8):1223-5. Epub 2007 May 22.

PMID:
17517053
[PubMed - indexed for MEDLINE]
14.

Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, Shibayama H, Sugahara H, Takai E, Zhang X, Machii T, Kanakura Y.

Int J Hematol. 2002 Dec;76(5):427-35.

PMID:
12512837
[PubMed - indexed for MEDLINE]
15.

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C.

Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26.

PMID:
18657349
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

Heinrich MC, Blanke CD, Druker BJ, Corless CL.

J Clin Oncol. 2002 Mar 15;20(6):1692-703. Review.

PMID:
11896121
[PubMed - indexed for MEDLINE]
Free Article
17.

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.

PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.

PMID:
19789626
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

PMID:
16638875
[PubMed - indexed for MEDLINE]
Free Article
19.

Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.

Advani AS.

Curr Hematol Malig Rep. 2006 Jun;1(2):101-7. doi: 10.1007/s11899-006-0020-9. Review.

PMID:
20425339
[PubMed - indexed for MEDLINE]
20.

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ.

Blood. 2000 Aug 1;96(3):925-32.

PMID:
10910906
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk